oncolytics.blogspot.com

The Oncolytic Times: Oncolytics Biotech News and Information

Tuesday, August 12, 2008. US NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with Reolysin. The primary objectives of the study are to assess the antitumour effects of Reolysin in patients with metastatic malignant melanoma, as well as the safety profile of Reolysin. Secondary objectives include assessment of progression free survival and overall survival. Approximately 60,000 people are diagnosed with melanoma in the U.S. every year. Wednesday, July 30, 2008. Oncolytics experienced a st...

http://oncolytics.blogspot.com/

OVERVIEW OF oncolytics.blogspot.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

19

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR ONCOLYTICS.BLOGSPOT.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

June

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Friday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 2.3 out of 5 with 4 reviews

5 star

0

4 star

1

3 star

1

2 star

0

1 star

2

Hey there! Start your review of oncolytics.blogspot.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

0.2 seconds

FAVICON PREVIEW

16x16
32x32

CONTACTS AT ONCOLYTICS.BLOGSPOT.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

19

SSL

EXTERNAL LINKS

0

SITE IP

216.58.194.193

LOAD TIME

0.234 sec

SCORE

6.2

PAGE TITLE

The Oncolytic Times: Oncolytics Biotech News and Information | oncolytics.blogspot.com Reviews

<META> DESCRIPTION

Tuesday, August 12, 2008. US NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with Reolysin. The primary objectives of the study are to assess the antitumour effects of Reolysin in patients with metastatic malignant melanoma, as well as the safety profile of Reolysin. Secondary objectives include assessment of progression free survival and overall survival. Approximately 60,000 people are diagnosed with melanoma in the U.S. every year. Wednesday, July 30, 2008. Oncolytics experienced a st...

<META> KEYWORDS

1 posted by

2 author

3 29 comments

4 labels press release

5 second quarter highlights

6 significant clinical advances

7 cyclophosphamide trial

8 preclinical advances

9 therapy

10 manufacturing

CONTENT

Page content here

KEYWORDS ON PAGE

posted by,author,29 comments,labels press release,second quarter highlights,significant clinical advances,cyclophosphamide trial,preclinical advances,therapy,manufacturing,intellectual property,no comments,conference call details,here,labels news,events

SERVER

GSE

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

The Oncolytic Times: Oncolytics Biotech News and Information | oncolytics.blogspot.com Reviews

https://oncolytics.blogspot.com

Tuesday, August 12, 2008. US NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with Reolysin. The primary objectives of the study are to assess the antitumour effects of Reolysin in patients with metastatic malignant melanoma, as well as the safety profile of Reolysin. Secondary objectives include assessment of progression free survival and overall survival. Approximately 60,000 people are diagnosed with melanoma in the U.S. every year. Wednesday, July 30, 2008. Oncolytics experienced a st...

INTERNAL PAGES

oncolytics.blogspot.com

1

The Oncolytic Times: Oncolytics Biotech News and Information: Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating Reolysin in Combination with Paclitaxel and Carboplatin

http://oncolytics.blogspot.com/2008/06/oncolytics-biotech-inc-announces-us.html

Thursday, June 19, 2008. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating Reolysin in Combination with Paclitaxel and Carboplatin. This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Subscribe to: Post Comments (Atom). Enter your search terms. Subscribe in a reader. Have new posts delivered to your inbox. Enter your email address here:. Oncoly...

2

The Oncolytic Times: Oncolytics Biotech News and Information: Oncolytics Biotech Inc. to Present at BIO 2008 International Convention

http://oncolytics.blogspot.com/2008/06/oncolytics-biotech-inc-to-present-at.html

Thursday, June 12, 2008. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention. CALGARY, June 12 - Oncolytics Biotech Inc., announced today that Dr. Brad Thompson, President and CEO of Oncolytics, will participate in two separate presentations at the BIO 2008 International Convention. Dr Thompson is scheduled to provide a corporate overview of the Company on Tuesday, June 17th at 3:30 pm PT at the BIO Business Forum. Subscribe to: Post Comments (Atom). Enter your search terms. Oncolytic...

3

The Oncolytic Times: Oncolytics Biotech News and Information: February 2008

http://oncolytics.blogspot.com/2008_02_01_archive.html

Saturday, February 23, 2008. Oncolytics Biotech Inc. to Present at Oncology Biologics Development Primer. CALGARY, Alberta, - - February 21, 2008 – Dr. Matt Coffey, Chief Scientific Officer of Oncolytics Biotech Inc. (TSX: ONC. For more information about the conference, please visit www.isbtc.org. And click on “Oncology Biologics Development Primer.”. Tuesday, February 19, 2008. Virus as Viable Drug. The reovirus is Mother Nature's own cancer-killer." Provocative headlines from PharmExec.com. Oncolytics ...

4

The Oncolytic Times: Oncolytics Biotech News and Information: November 2007

http://oncolytics.blogspot.com/2007_11_01_archive.html

Thursday, November 29, 2007. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference. For more information about the conference, please visit www.informa-ls.com/vaccines. Wednesday, November 28, 2007. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent. 11/27/2007 7:08:59 AM ET. CALGARY, AB - - November 27, 2007 - Oncolytics Biotech Inc. (TSX: ONC. 8220;Oncolytics”) today announced that it has been granted U.S. Patent 7,300,650. About Oncolytics Biotech Inc.Oncolytics is...

5

The Oncolytic Times: Oncolytics Biotech News and Information: Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with Reolysin

http://oncolytics.blogspot.com/2008/06/oncolytics-biotech-inc-announces-start.html

Tuesday, June 10, 2008. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with Reolysin. REOLYSIN is an exciting agent to investigate in patients with ovarian cancer," said Dr. Cohn. "Targeting a specific alteration commonly present in these tumors will hopefully lead to efficacy with minimal toxicity.". Subscribe to: Post Comments (Atom). Enter your search terms. Subscribe in a reader. Have new posts delivered to your inbox. Enter your email address here:.

UPGRADE TO PREMIUM TO VIEW 14 MORE

TOTAL PAGES IN THIS WEBSITE

19

OTHER SITES

oncolys.com

Oncolys BioPharma Inc. || オンコリスバイオファーマ株式会社

テロメスキャン OBP-401 and OBP-1101.

oncolysis.com

The domain oncolysis.com is for sale. To purchase, call Afternic at 1 339-222-5147 or 866-836-6791. Click here for more details.

oncolysis.net

oncolysis.org

oncolyticimmunotherapy.com

Find it | Fight It | Lyse & Learn. Explore Oncolytic Immunotherapy

Website is under maintenance. Please check back later.

oncolytics.blogspot.com

The Oncolytic Times: Oncolytics Biotech News and Information

Tuesday, August 12, 2008. US NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with Reolysin. The primary objectives of the study are to assess the antitumour effects of Reolysin in patients with metastatic malignant melanoma, as well as the safety profile of Reolysin. Secondary objectives include assessment of progression free survival and overall survival. Approximately 60,000 people are diagnosed with melanoma in the U.S. every year. Wednesday, July 30, 2008. Oncolytics experienced a st...

oncolytics.ca

http://oncolytics.ca/

To view the non-framed versi on.

oncolyticsbiotech.com

Oncolytics Biotech, Inc. (ONCYF)

What Does REOLYSIN Do? Oncolytics Biotech Inc. is developing REOLYSIN , a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies. How We're Developing REOLYSIN as an. Taking advantage of stressed tumor cells to initiate cell lysis.

oncolyticvirotherapies.com

Oncolytic Virotherapy Summit 2017 | Hanson Wade

December 5-6th, 2017. San Diego, CA. The Annual Oncolytic Virotherapy Summit is dedicated to foster the next wave of genetically modified viruses. That target, replicate and kill cancer cells in a clinical setting, spurred on by advanced genetic engineering techniques. By better understanding o ncolytic platforms, preclinical virotherapy models, clinical strategy and scalable manufacture. Of viruses, Oncolytic Virotherapy Summit is the only industry-focused gathering. T: 44 (0)20 3141 8700. San Diego, CA.

oncolyticvirus.com

The domain oncolyticvirus.com is for sale. To purchase, call Afternic.com at 1 781-373-6847 or 855-201-2286. Click here for more details.

oncolyticvirus.info

アコム審査基準ナビ〜甘いって本当？主婦もバイトも学生も即日融資可能！

パートやアルバイトなどでしっかり収入があるのに職歴が短い自営業だから納得の行かない理由で、キャッシングやクレジットカードを諦めていませんか. クレジットカードの審査は、一般的に金融系流通系信販系銀行系の順番で規準が厳しいと言われています。本当は返済能力のあるのに、雇用期間の短さなどで審査に落とされてしまうのは、悔しくはありませんかアコムなら、その点をしっかり審査してくれますクレジットカードの審査を恐れてはダメまずは、3秒審査にトライ審査回答も最短たったの30分.